compass biotechnologies inc - BNGI

BNGI

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 100.00K

Last Updated:

Dec 13, 2024, 12:01 PM EDT

Company Overview: compass biotechnologies inc - BNGI

BNGI Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.00

Market Cap

$0.00

Shares Outstanding

525.37M

Public Float

521.48M

Beta

-37.40

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.00

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

409.69K

 

BNGI Performance

1 Week
 
0.00%
 
1 Month
 
0.00%
 
3 Months
 
0.00%
 
1 Year
 
0.00%
 
5 Years
 
N/A
 

BNGI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About compass biotechnologies inc - BNGI

BANGI, Inc. focuses on the acquisition, ownership and management of properties leased to experienced, state-licensed operators for regulated use of cannabis facilities. The company was founded on May 12, 2004 by Joseph Sinkule and Garth Likes and is headquartered in Gross Point Farms, MI.

BNGI At a Glance

BANGI, Inc.
41000 Woodward Avenue
Bloomfield Hills, Michigan 48304
Phone 1-947-777-0353 Revenue 0.00
Industry Biotechnology Net Income -317,809.00
Sector Health Technology Employees N/A
Fiscal Year-end 01 / 2020
View SEC Filings

BNGI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.302

BNGI Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

BNGI Liquidity

Current Ratio 0.079
Quick Ratio 0.079
Cash Ratio N/A

BNGI Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -284.579
Return on Equity N/A
Return on Total Capital 25.869
Return on Invested Capital N/A

BNGI Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -41.642
Total Debt to Total Assets 458.093
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -35.277
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Compass Biotechnologies Inc - BNGI

Collapse All in section
All values USD millions. 2016 2017 2018 2019 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - -
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - -
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - -
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2016 2017 2018 2019 5-year trend
SG&A Expense
- 179.59K 205.14K 20.00K
Research & Development
- - - 7.50K
-
Other SG&A
- 179.59K 197.64K 20.00K
SGA Growth
+314.62% +14.23% -90.25% -100.00%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 50.00K
-
EBIT after Unusual Expense
- (229.59K) (205.14K) (20.00K)
Non Operating Income/Expense
- - (192.64K) (39.38K)
-
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 171.71K 220.32K 278.43K
Interest Expense Growth
- - +28.31% +26.38%
-
Gross Interest Expense
- 171.71K 220.32K 278.43K
Interest Capitalized
- - - -
-
Pretax Income
(229.59K) (376.85K) (432.96K) (317.81K)
Pretax Income Growth
-108.03% -64.14% -14.89% +26.60%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(229.59K) (376.85K) (432.96K) (317.81K)
Minority Interest Expense
- - - -
-
Net Income
(229.59K) (376.85K) (432.96K) (317.81K)
Net Income Growth
-108.03% -64.14% -14.89% +26.60%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(229.59K) (376.85K) (432.96K) (317.81K)
Preferred Dividends
- - - -
-
Net Income Available to Common
(229.59K) (376.85K) (432.96K) (317.81K)
EPS (Basic)
-0.0004 -0.0002 -0.0001 -0.0001
EPS (Basic) Growth
- -100.00% +50.00% +50.00%
Basic Shares Outstanding
541.59M 2.20B 2.84B 3.95B
EPS (Diluted)
-0.0004 -0.0002 -0.0001 -0.0001
EPS (Diluted) Growth
- -100.00% +50.00% +50.00%
Diluted Shares Outstanding
541.59M 2.20B 2.84B 3.95B
EBITDA
- - (179.59K) (205.14K)
-
EBITDA Growth
- - -314.66% -14.23%
-
EBITDA Margin
- - - -
-

Compass Biotechnologies Inc in the News